The latest update is out from Sanofi ( (SNY) ).
In March 2025, Sanofi announced positive results from the ADEPT phase 2/3 study of Dupixent (dupilumab) for treating moderate-to-severe bullous pemphigoid (BP), a chronic skin disease. The study, presented at the American Academy of Dermatology Annual Meeting, showed that Dupixent significantly improved disease remission, reduced severity, and decreased the need for corticosteroids compared to placebo. These findings support Dupixent’s potential as the first targeted treatment for BP, with regulatory submissions under review in the US and EU. The FDA has granted priority review status, with a decision expected by June 2025.
More about Sanofi
Sanofi is a global healthcare leader in the pharmaceutical industry, primarily focusing on developing and marketing therapeutic solutions. The company is known for its innovative medicines and vaccines, targeting a wide range of diseases and conditions, with a significant emphasis on research and development to address unmet medical needs.
YTD Price Performance: 22.95%
Average Trading Volume: 2,601,426
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $149.1B
See more insights into SNY stock on TipRanks’ Stock Analysis page.